Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that causes hyperactivity and impulsivity in children and adults. If left untreated ...
Launches of Tuzulby® methylphenidate prolonged-release chewable tablets and Paxneury® guanfacine prolonged-release tablets, also in 5mg, 6mg, and 7mg strengths Two differentiated treatments exemplify ...
SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug ...
Adult ADHD has emerged as a significant health concern in the United States, with approximately one-quarter of adults suspecting they may have undiagnosed attention deficit hyperactivity disorder.
Despite decades of research, these ADHD myths still affect how people understand attention and behavior.
The Victorian government has announced it will train 150 GPs to diagnose and start treatment for attention deficit ...
Following the changes made today, more New Zealanders with ADHD will have faster access to support as a result of changes to ...
Attention Deficit Hyperactivity Disorder (ADHD) medication use rose threefold over 13 years, with adult women showing the steepest climb.
SHANGHAI, Jan. 8, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results